The Patent Lawyer - Logo
Rotating Image Link
Published November 18, 2026

The Unified Patent Court (UPC) has confirmed that it can take measures to prevent patent proprietors from using divisional applications or withdrawing patent texts to frustrate ongoing validity proceedings, in a potentially significant procedural ruling involving pharmaceutical companies Sandoz AG and Novo Nordisk A/S.

In a procedural order issued on October 22, 2026, the UPC’s Central Division in Milan considered a series of additional requests brought by Sandoz in revocation proceedings against Novo Nordisk’s European patent with unitary effect EP 3 689 365. The dispute concerns a semaglutide composition for the prevention or treatment of type 2 diabetes, administered once weekly at a dose of 1.0 mg.

The court rejected Sandoz’s request for an abstract declaration that the composition was obvious, but confirmed that it had jurisdiction to consider measures aimed at preventing patent withdrawal and divisional filing strategies from undermining pending revocation proceedings.

The decision addresses a potentially important issue for pharmaceutical patent litigation: whether a proprietor can avoid an adverse validity determination by withdrawing a challenged patent while continuing to pursue substantially equivalent subject matter through related divisional applications.

The ‘divisional game’

Divisional applications allow patent applicants to pursue separate applications covering subject matter disclosed in an earlier parent application. They serve legitimate purposes, including protecting distinct aspects of an invention, but their strategic use can create difficulties for companies challenging pharmaceutical patent portfolios.

The so-called ‘divisional game’ involves a patent proprietor withdrawing a challenged patent before a final validity determination, while continuing to pursue substantially similar protection through divisional applications. This can leave generic manufacturers facing repeated validity challenges and uncertainty over whether they can bring competing products to market.

Sandoz brought proceedings before the UPC seeking revocation of Novo Nordisk’s EP 3 689 365 patent, principally on grounds of lack of inventive step and added matter. A related divisional application, EP 4 406 593, was pending before the European Patent Office (EPO) when the court considered the dispute.

Alongside its revocation action, Sandoz sought three additional forms of relief intended to prevent the proceedings from being frustrated by the alleged divisional strategy. These included a declaration that a specified semaglutide composition was obvious at the relevant priority date, a declaration concerning the validity of substantially similar claims in related patents, and an order preventing Novo Nordisk from withdrawing its approval of the patent text before the EPO under Article 113(2) of the European Patent Convention (EPC).

UPC rejects abstract obviousness declaration

The court upheld Novo Nordisk’s preliminary objection to Sandoz’s first additional request, finding that it lacked jurisdiction to grant the abstract declaration of obviousness sought. Sandoz had requested a declaration that a semaglutide composition administered subcutaneously once weekly at a dose of 1.0 mg for treating or preventing type 2 diabetes was obvious at the relevant priority date.

The court distinguished this request from conventional ‘Arrow’ declarations, which establish whether an identified product, process or commercial activity was known or obvious at a particular date. It noted that Sandoz had not identified a specific product, process, intended commercial act or market activity to which the declaration would relate.

Instead, the request was directed at the patentability of subject matter independently of an identified patent or commercial activity. The court also expressed concern that granting such broadly framed relief could affect the rights of third parties that were not involved in the proceedings. Accordingly, the request was declared inadmissible in its present form.

Revocation proceedings may continue following patent withdrawal

The court took a different approach to Sandoz’s second request, which sought a declaration that substantially similar claims in related European or Unitary Patents would lack inventive step. It rejected Novo Nordisk’s jurisdictional objection, confirming that the UPC could consider this form of relief as a means of protecting the effectiveness of pending revocation proceedings. In particular, the court indicated that withdrawing a challenged patent would not automatically mean that the UPC lost jurisdiction over the pending action.

Under Rule 360 of the UPC Rules of Procedure, the court can dispose of proceedings where an action has become devoid of purpose. However, it confirmed that it could decline to terminate a revocation action if the claimant retained a concrete and continuing interest in obtaining a determination of validity.

Where evidence established that a patent proprietor had used a divisional strategy to frustrate the proceedings, the court could potentially continue to determine the validity of the withdrawn patent, including whether it lacked inventive step. The court also addressed the potential implications for related divisional patents. It indicated that a validity determination could become relevant to claims in the same patent family that substantially corresponded to the subject matter already adjudicated.

However, such a determination would not automatically invalidate a granted divisional patent. The court would need to consider the circumstances of the case, including whether the divisional had been used to circumvent the earlier validity determination and the extent to which its claims reproduced or substantially corresponded to the subject matter previously considered. The court accepted that it had jurisdiction to consider Sandoz’s request, but left its substantive admissibility and merits for the main proceedings.

UPC confirms power to restrict patent withdrawals before the EPO

The court also rejected Novo Nordisk’s jurisdictional objection to Sandoz’s third request, which sought an order preventing the company from withdrawing its approval of the patent text before the EPO under Article 113(2) EPC. The provision makes the maintenance of a European patent dependent on the proprietor’s approval of the text in which the EPO intends to grant or maintain it. Withdrawing that approval can therefore prevent a patent from proceeding in the form under consideration.

The Central Division confirmed that it had the power to grant protective measures restraining a patent proprietor from taking such action where necessary to preserve the effectiveness of pending revocation proceedings. However, it did not grant the injunction requested by Sandoz. The court found that the application was not supported by sufficiently specific factual circumstances and indicated that any future request would need to establish the relevant requirements, including urgency, necessity and proportionality.

The court’s reasoning was based on its ability to protect the effectiveness of the jurisdiction expressly conferred on it under the UPC Agreement, rather than treating the power to grant such relief as unlimited or independent of its statutory jurisdiction.

No finding of procedural abuse

Despite its willingness to consider measures against the alleged divisional strategy, the court did not find that Novo Nordisk had actually abused its patent rights. It considered that the existence of a pending divisional application and Novo Nordisk’s reservation of its right to file further divisional applications were insufficient, without additional evidence, to establish procedural misconduct.

The order therefore leaves open the circumstances in which legitimate patent portfolio management might cross the line into procedural abuse. It also highlights the importance of distinguishing between confirming that the UPC has jurisdiction to grant a particular form of relief and establishing that the facts of an individual case justify granting it.

Implications for pharmaceutical patent litigation

The decision provides an important indication of the UPC’s willingness to protect the effectiveness of its proceedings against strategies that could otherwise undermine patent validity challenges. For generic manufacturers, the ruling potentially offers an additional means of preventing patent proprietors from avoiding judicial scrutiny by withdrawing challenged rights while continuing to pursue substantially equivalent protection through divisional applications.

For patent proprietors, it highlights the need to consider how withdrawal decisions and divisional filing strategies may be viewed in the context of ongoing litigation. The possibility that a revocation action could continue following withdrawal of the challenged patent may also affect litigation strategy and settlement considerations.

The decision does not resolve the underlying validity dispute or establish that all related divisional claims will be affected by an adverse determination. Instead, it confirms that the UPC can consider the circumstances of a particular case and take appropriate measures where necessary to prevent its proceedings from being frustrated.

The Central Division also granted permission to appeal the order, potentially paving the way for further guidance from the UPC Court of Appeal on the limits of the court’s jurisdiction and its ability to intervene in divisional patent strategies.

As pharmaceutical patent disputes increasingly involve complex families of related applications, the ruling could have significant implications for how generic manufacturers and patent proprietors approach revocation proceedings and patent portfolio management before the UPC.

Elizabeth Jordan

Written by Elizabeth Jordan

Senior Industry Engagement Manager, CTC Legal Media

haynes boone

You may also like…

Contact us to write for out Newsletter

The Patent Lawyer - Logo

Subscribe To Our Newsletter

Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!

You have Successfully Subscribed!